Gyrodyne, LLC — Q3 2023 Form 10-Q
Reporting period: Quarter ended September 30, 2023; financial statements present the nine months ended September 30, 2023. Gyrodyne is pursuing entitlements and sales of its remaining New York medical-office and industrial properties, with the intention to distribute remaining proceeds and dissolve. It reports on the liquidation basis of accounting, so conventional income statements and cash-flow statements are not presented.
Financial position and operating metrics
| Metric | September 30, 2023 | Comparison / detail |
|---|---|---|
| Real estate held for sale | $53.67 million | Unchanged from December 31, 2022 |
| Cash and cash equivalents | $2.68 million | Down from $4.08 million at December 31, 2022 |
| Total assets | $56.44 million | Down from $57.89 million |
| Total liabilities | $26.41 million | Down from $27.52 million |
| Loans payable | $9.55 million | Down from $9.76 million |
| Net assets in liquidation | $30.03 million | Down $338,962 from year-end 2022 |
| Estimated distribution value | $20.25 per share | Versus $20.48 at December 31, 2022; estimate, not a promised distribution |
- The $338,962 decrease in net assets was attributed mainly to shareholder-activism response and related professional costs, partly offset by reduced retention-plan benefits. Real estate liquidation value was not remeasured during the nine-month period.
- Nine-month operating cash-flow components included $2.34 million in rent and reimbursements, $1.26 million in operating costs and reported net operating income of $1.80 million. Corporate expenditures were $2.61 million; net interest expense was $250,388; real-estate capital expenditures were $197,689 and entitlement costs were $400,253.
- The filing does not provide a clear conventional revenue, net income, cash-flow-from-operations, or margin figure for the quarter; its liquidation-basis statements do not report those standard measures.
- Debt comprises two Flowerfield loans bearing fixed interest at 3.85% and a Cortlandt Manor mortgage bearing 3.75%. The mortgage balance was $4.78 million; the company reported compliance with the Flowerfield loan covenants. The mortgage is scheduled to mature in 2026; the Flowerfield loans mature in 2028.
Material developments and outlook
- Smithtown granted preliminary approval in 2022 for an eight-lot Flowerfield subdivision, but a pending Article 78 proceeding seeks to overturn the related environmental findings and approval. The company and Smithtown are defending the approval; a motion to dismiss remained undecided at quarter-end, following reassignment to a different judge. The case could take two years or more.
- Cortlandt adopted a Medical Oriented Zoning District in March 2023, designating 154,000 square feet of total density: 150,000 square feet for medical use and 4,000 for retail. Final subdivision and site-plan approvals remain outstanding.
- Management targets final Flowerfield subdivision approval around mid-2024, Cortlandt Manor subdivision approval potentially in Q4 2024, and completion of property sales and liquidation by year-end 2024. These are expectations, not assurances; litigation, regulatory delays, labor shortages and transaction conditions could extend the timeline.
- Management estimates gross real-estate sale proceeds of $53.67 million and net assets/distributable cash of approximately $30.03 million, or $20.25 per existing share, based on September 30 estimates and assumed liquidation by December 31, 2024. The company estimated a further $1.08 million of entitlement costs through the liquidation period. Property values and costs rely significantly on estimates and Level 3 inputs; actual proceeds and distributions may differ materially.
- Following quarter-end, shareholders approved a restricted-stock plan. On November 14, 2023, 91,628 shares were issued to former director participants in exchange for forfeiting $2.70 million of retention-plan benefits. The filing presents pro forma net assets of $32.73 million, or $20.79 per share, using 1,574,308 shares; this is distinct from the reported quarter-end figure.
Risks, contingencies and unusual items
- The Flowerfield legal challenge could delay or undermine subdivision approval and asset sales. The company also remains bound by a 2015 settlement requiring arm’s-length property sales at or above 2014 appraised values.
- Star Equity withdrew its director nominations and shareholder proposal under a cooperation agreement. Activism-related response and compensation-plan costs totaled approximately $1.2 million through September 30; the company is pursuing insurance recovery above a $500,000 deductible.
- Amendment No. 5 to the retention bonus plan returned an estimated $1.14 million of retired-director benefits to the company, revised bonus rates and changed vesting and payment terms. The director portion was subsequently exchanged for restricted shares.
- Management says cash is expected to fund entitlement work and liquidation, but is considering supplemental financing. Rental receipts net of property costs are below combined annual corporate, capital and entitlement costs, creating a cash use absent asset-sale proceeds. Insufficient cash could eliminate distributions; shareholders could face repayment claims if distributions are made before creditor claims are satisfied.
- Other uncertainties include commercial-real-estate conditions, inflation and interest rates, recession risk, tenant concentration and renewals, healthcare-sector regulation, remote work and telemedicine, and the timing and cost of approvals and litigation.
Important facts for investors to verify
- Whether the Article 78 court challenge is resolved and whether Flowerfield receives final subdivision approval.
- Progress toward final Cortlandt Manor approvals, purchase agreements and property closings, and any changes to management’s year-end 2024 liquidation assumption.
- Realized sale prices versus the $53.67 million estimated gross proceeds, entitlement and liquidation costs, debt repayments, and the resulting actual distributions per share.
- The company’s funding needs and liquidity runway if property sales are delayed, including any supplemental financing and deferred vendor payments.
- The effect of the 91,628-share issuance and related retention-plan exchange on fully diluted share count, incentives and per-share liquidation value.